1. Introduction
The novel coronavirus disease 2019 (COVID-19) is caused by the infection of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has swiftly
spread around the globe in the past year [1, 2, 3]. Although the scientific community
is actively exploring several treatments (e.g., remdesivir, immune modulators and
COVID-19 vaccinations) that would potentially combat with COVID-19 [4, 5, 6, 7], the
virus spreading still reached into the billions [8, 9]. A retrospective cohort
study has analyzed 76 critically ill cases of COVID-19 from General Hospital of
the Central Theatre Command and Wuhan Pulmonary Hospital from December 2019 to
March 2020. Thymosin-1 treatment manifested significant reduction in
the mortality of severe COVID-19 patients as compared with untreated group
(30.00% vs. 11.11%, p = 0.044) [10]. It thus indicated that
thymosin might have the potential therapeutic efficacy for preventing critical
COVID-19 infection.
Thymosin-1, an immune-modulating polypeptide hormone with 28-amino
acids which is mainly produced by thymic
epithelial cells [11, 12], can effectively restore T cells by enhancing their
differentiation and inhibiting apoptosis [13, 14]. It could also modulate
proinflammatory cytokine storm [15] and chemokines production [16]. Therefore,
thymosin-1 has been widely used for anti-virus clinical treatments,
which is approved as an immune adjuvant to treat hepatitis B (HBV) [17, 18] and
hepatitis C (HCV) [19, 20]. The latest multicenter retrospective study which has
enrolled 334 COVID-19 patients suggested thymosin 1 treatment can
markedly decrease 28-day mortality and attenuate acute lung injury in critical
type COVID-19 patients (Hazards Ratios: 0.11, 95% confidence interval:
0.02–0.63, p = 0.013) [21]. Thymosin-1 group was also
demonstrated with much shorter RNA shedding duration of SARS-CoV-2 (13
days vs. 16 days, p = 0.025) and hospital stay (14 days
vs. 18 days, p 0.001) [22]. Nevertheless, the underlying
mechanism of anti-viral effect of thymosin-1 was only interpreted to
strengthen immune response by the restoration of lymphocytopenia and reversion of
exhausted T cells [23, 24]. Further mechanistic targets of thymosin-1
deserved to be clarified in severe COVID-19 treatment.
In this study, we revealed a novel regulatory mechanism of thymosin-1 in preventing SARS-CoV-2 infection, which was evidenced
from the data of network pharmacological studies and molecular verifications on
human lung epithelial cells. It has shed light on the potential underlying
mechanism that thymosin-1 impairs ACE2 expressions of human lung
epithelial cells by binding with ACE, which consequently reduces the host
receptors of SARS-CoV-2. This study implicates that therapeutic strategy of
thymosin-1 may help to early prevent COVID-19 diffusion in lung
epithelial cells.
2. Materials and methods
Collection of all targets of COVID-19 and thymosin-1. Based
on the available tools of Swiss Target Prediction [25], therapeutic targets of
thymosin-1 were collected by the tool of SuperPred. The above process
of targets prediction was carried out in five different species in order to close
paralogs and orthologs. Then “smiles” formats of thymosin-1 were
imported into Swiss Target Prediction to predict its putative targets. Of note,
these high-probability targets were only limited to Homo sapiens and all
selected targets were identified in Therapeutic Target Database and Comparative
Toxicogenomic Database. Subsequently, the disease-screening tool of GeneCards was
employed to harvest COVID-19-associated targets [26]. Ultimately, the identified
targets of COVID-19 and thymosin-1 were further intersected to obtain
the shared targets of thymosin-1 treating COVID-19.
The protein-protein interaction network of all shared targets. 19 shared
biotargets were merged to draft a connective network of thymosin-1
treating COVID-19 by using a STRING tool [27]. Then Cytoscape software was
employed to draft the protein-protein interaction (PPI) network of
thymosin-1 treating COVID-19 [28]. Selected from all nodes of the
network, we treat those with more than 2-fold of the median degree as the major
hubs. They are analysed by several critical topological properties according to
the number of node links, the number of shortest paths between pairs of nodes,
the sum of the distances of node to all other nodes and K-coreness. Subsequently,
KEGG pathway enrichment of the main targets was analysed by DAVID webserver
(https://david.ncifcrf.gov/). To obtain a better understanding of the biological
function and molecular interaction, the topological parameter of network settings
for anti-COVID-19 targets played by thymosin-1 were identified through
the stand-alone software tool FunRich (version 3.0,
http://www.funrich.org/download) [29].
Assay of the KEGG pathway enrichment of thymosin-1 treating
COVID-19. Eight therapeutic targets of thymosin-1 against
COVID-19 were uploaded into the online Database of Functional Annotation
Bioinformatics Microarray Analysis (DAVID) to search for the top activated and
inactivated signaling pathways of thymosin-1 treating COVID-19.
According to the settings of the reported -Log p value, the bar graph of
activated and inactivated signaling pathways of thymosin-1 treating
COVID-19 were respectively created and illustrated [30].
Binding kinetics assay. The kinetics of thymosin-1 binding
was evaluated through surface plasmon resonance (SPR) using a
PlexArray HT system (Plexera LLC, Woodinville, WA, USA).
ACE purified protein (ICA004Mu01, LMAI Bio), SARS-CoV-2 spike glycoprotein
(Abcam, ab273063) and Thymosin-1 (Sigma-Aldrich, T3410, CAS No.
62304-98-7) were purchased from commercial sources. In brief, ACE purified
protein was immobilized on a biosensor chip (Graft-to-PCL). The specific
interactions of thymosin-1 with the immobilized ACE purified protein
were assessed. Thymosin-1 was analyzed at a flow rate of 1 L/min
with 0.01 M PBS running buffer and contact time of 200 s. The surface was washed
and regenerated with a 0.125% SDS buffer at a flow rate of 2 L/min for
200 s followed by 30-min waiting time for dissolution after each experiment. The
competition binding assay was same as above, except that SARS-CoV-2 spike
glycoprotein was fixed on the chip and then dipped into wells containing ACE2
purified protein alone or with doses of thymosin-1. The analyses were
performed in PLEXERA SPR Date Analysis Module (DAM).
Fluorometric detection of ACE and ACE2 enzymatic activity. Purified human ACE
protein and human ACE2 protein were purchased from LMAI Bio (ICA004Mu01) and
OriGene Technologies (TP720353). Then standard curve preparation and fluorometric
substrates measurements were instructed as the standard protocol of Angiotensin I
Converting Enzyme Activity Assay Kit (Fluorometric) (BioVision, Catalog #
K227-100) and Angiotensin II Converting Enzyme Activity Assay Kit (Fluorometric)
(BioVision, Catalog # K897-100).
Western blotting analysis. Proteins were extracted by using RIPA Lysis Buffer
(P0013, Beyotime, China) and quantified by using a BCA kit (P0009, Beyotime,
China). Twenty micrograms of each protein sample were separated by 10% SDS-PAGE
and transferred to a polyvinylidene difluoride membrane. The membranes were
blocked with 5% BSA and incubated with primary antibodies (ACE2, Abcam,
ab108252; ACE, GeneTex, GTX54938; Ang I, LifeSpan BioSciences, LS-C301221; Ang
II, LifeSpan BioSciences, LS-C299822; angiotensin (1–7), LifeSpan BioSciences,
LS-C705843; angiotensin (1–9), LifeSpan BioSciences, LS-C664040;
-actin, A5441, Sigma) for 10 h at 4 C. The membranes were
rinsed five times with PBS containing 0.1% Tween 20 and incubated for 1 h with
appropriate horseradish peroxidase-conjugated secondary antibody at 37
C. Membranes were extensively washed with PBS containing 0.1% Tween 20
for three times. The signals were stimulated with enhanced chemiluminescence
substrate (NEL105001 EA, PerkinElmer) for 1 min and detected with a Bio-Rad
ChemiDoc MP System (170-8280).
Small interfering RNAs (siRNAs). siRNAs target sequence for human ACE
(Genbank No. NM_000789.2) is 5-GCA TCA CCA AGG AGA ACT AdTdT-3 and the
control siRNA target sequence is 5-UUC UCC GAA CGU GUC ACG UdTdT-3,
which were both synthesized at Genechem Services (Shanghai, China). BEAS-2B cells
and BEP-2D cells were cultured with growth medium without BSA one day before
transfection. Then we diluted 20 pmol siRNA oligomer in 50 L
Gibco™ Opti-MEM™ and mix with Lipofectamine 2000
for 6 hours incubation. Culture medium was replaced as the BSA-containing medium
and gene knockdown was detected by the assay of western blotting and RT-qPCR.
RT-qPCR. Total RNA was extracted with Trizol (Invitrogen, USA) and cDNA
synthesis was performed by using the ReverTra Ace qPCR RT Kit (Toyobo, Japan).
Real-time quantitative PCR was performed using PowerUpTM SYBRTM Green Master Mix
kit for specific amplification (Thermo Fisher, USA). Melting curve analysis
confirmed the formation of individual desired PCR products. Real-time PCR for
each gene was performed in three replicate trials and normalized to GAPDH
expression values.
Enzyme linked immunosorbent assay (ELISA). BEAS-2B siACE cells and
BEP-2D siACE cells as well as their control siRNA cells (3 10)
were seeded to incubate overnight for their cell adherence. Then they were all
treated with thymosin-1 (10 M, 20 M and 40 M) and
collected after 48 hours of thymosin-1 treatment. Ang-1 and Ang-2
levels were analyzed by the Quantikine human Ang-1 ELISA kit (R&D Systems,
Minneapolis, MN) and the Quantikine human Ang-2 ELISA kit (R&D Systems),
respectively. Angiotensin (1–7) and angiotensin (1–9) were detected by Ang 1–7
and Ang 1–9 ELISA kit (CUSABIO Biotech). These ELISA assays were performed as
recommended by the respective manufacturer. All experiments were
performed in triplicate.
Statistical analysis. Statistical analysis was conducted by GraphPad
Prism 8. After checking data for normal distribution and variance homogeneity,
continuous data were compared using multiple Student t tests or two-way ANOVA.
All p values are two-tailed, and p values 0.05 are
considered significant (*p 0.05, **p 0.01 and
***p 0.001). The data are represented as mean S.E.M. or the
median with 10 and 90 percentiles.
3. Results
Biological targets and PPI network of thymosin-1 treating COVID-19.
First of all, a total of 350 COVID-19-associated genes were identified according
to GeneCards database (score from 0.24 to 28.74). Meanwhile, 100 functional genes
of thymosin-1 were harvested from Swiss Target Prediction database
(probability rate from 6.42% to 14.01%), prior to further screening of 19
shared biological targets of thymosin-1 and COVID-19 (Fig. 1, left
panel). Then these 19 biotargets were used to further plot an optimal STRING PPI
network of thymosin-1 treating COVID-19 (Fig. 1, right panel).
Fig. 1.
All targets of thymosin-1 and COVID-19 were identified
and the shared targets of thymosin-1 treating COVID-19 for drawing the
PPI network. COVID-19, Corona Virus Disease 2019; PPI, protein-protein
interaction; CASP8, Caspase 8; UBE2I, Ubiquitin Conjugating Enzyme E2 I; HLA-A,
Histocompatibility Complex, Class I, A; ANPEP, Alanyl Aminopeptidase; PRKCE,
Protein Kinase C Epsilon; CASP3, Caspase 3; CASP6, Caspase 6; ACE, Angiotensin I
Converting Enzyme; CTSB, Cathepsin B; CTSL, Cathepsin L; MAPK8, Mitogen-Activated
Protein Kinase 8; FURIN, Paired Basic Amino Acid Cleaving Enzyme; NOS2, Nitric
Oxide Synthase 2; DPP4, Dipeptidyl Peptidase 4; PTGS2, Prostaglandin-Endoperoxide
Synthase 2; F10, Coagulation Factor X; HLA-DRB1, Major Histocompatibility
Complex, Class II, DR Beta 1; F11, Coagulation Factor XI; ADAM17, ADAM
Metallopeptidase Domain 17. CASP8; UBE21; HLA-A; ANPEP; PRKCE; CASP3; CASP6; ACE; CTSB; CTSL; MAPK8;
FURIN; NOS2; DPP4; PTGS2; F10; HLA-DRB1; F11; ADAM17.
Selection and identification of core targets in thymosin-1 treating
COVID-19. All interceptive targets in Venn diagram were imported into Cytoscape
software for detecting and analyzing the topological parameters of anti-COVID-19
targets played by thymosin-1 and function-related PPI network (Fig. 2A).
By calculating the interactions of 19 shared targets, the median degree of
freedom of the targets was identified as 3.2, and the maximum degree of freedom
was identified as 18.3, followed by the core target screening conditions ranged
from 8.1 to 16.7. Herein, a total of eight core targets were obtained involving
HLA-A, FURIN, DPP4, CTSL, CTSB, ACE, PTGS2 and HLA-DRB1 (Fig. 2B).
Fig. 2.
Selection and identification of core targets in
thymosin-1 treating COVID-19. (A) 19 candidate biotargets of
thymosin-1 and COVID-19 were identified, respectively. Then a PPI
network from these biotargets was illustrated by Cytoscape software, which showed
all possible molecular interactions. (B) Eight core biotargets of
thymosin-1 treating COVID-19 were identified according to
bioinformatics analysis using network pharmacology, including HLA-A, FURIN, DPP4,
CTSL, CTSB, ACE, PTGS2 and HLA-DRB1. COVID-19, Corona Virus Disease 2019; PPI,
protein-protein interaction.
Revelation of biological functions and pathways from the above 8 core targets.
All essential KEGG pathways of the above 8 core targets were obtained through the
DAVID database and Cytoscape software to draw a core target-related pathway
interaction network (Fig. 3). As results, the top 20 KEGG pathways (minor overlap
is 5 and p value cut-off is 0.01) were related to hepatitis B, influenza
A Chagas disease (American trypanosomiasis), apoptosis, cytokine-cytokine
receptor interaction, Epstein Barr virus infection, JAK-STAT signaling pathway,
amoebiasis, NF-kappa B signaling pathway, chemokine signaling pathway amyotrophic
lateral sclerosis (ALS), apoptosis-multiple species, prion diseases, allograft
rejection, epithelial cell signaling in helicobacter pylori infection, TGF-beta
signaling pathway, longevity regulating pathway, transcriptional mis-regulation
in cancer, microRNAs in cancer, Alzheimer’s disease (Fig. 4A). Furthermore, DAVID
database analysis also showed that pivotal biological processes of these core
targets were involved in negative regulation of pathways in chondroitin sulfate
degradation, MAPK signaling pathway, inflammatory mediator regulation of TRP
channels, pertussis, signaling pathways regulating renin-angiotensin system
(RAS), pluripotency of stem cells, p53 signaling pathway, oxytocin signaling
pathway, complement and coagulation cascades, steroid hormone biosynthesis,
arachidonic acid metabolism and negative regulation of phospholipase D signaling
pathway (Fig. 4B).
Fig. 3.
Cluster assays showed a PPI network from the core targets
connected with top 20 activated signaling pathways in thymosin-1
treating COVID-19. COVID-19, Corona Virus Disease 2019; PPI, protein-protein
interaction.
Fig. 4.
Enrichment analyses showed the top 20 activated (A) and 11
inactivated (B) functional processes, molecular mechanism of thymosin-1
treating COVID-19. COVID-19, Corona Virus Disease 2019.
Study of binding kinetics between thymosin-1 and ACE. It was
reported that thymosin-1 binds to N-domain of ACE with the binding
energy of –22.87 kcal/mol by molecular docking, which clarified the potential
mechanism of thymosin-1 treatment in antioxidant and anti-hypertensive
effect [31]. In this study, the binding kinetics between thymosin-1
and ACE were investigated by the assay of surface plasmon resonance
(SPR), and the changes in refractive index on a chip coated with the protein were
measured to evaluate ligand binding (Fig. 5A). The dissociation constants
(K) in the low nanomolar range were obtained for thymosin-1 upon
titrating over immobilized ACE (K value was 17.4 nM). The slow dissociation
rates of inhibitors from the target protein are considered to be beneficial for
drug efficacy and selectivity in vivo due to the high concentration of
the drug near the target, such as EGFR inhibitor lapatinib [32, 33].
The remarkably slow K measured for
thymosin-1 (1.01 10 s), corresponds to a
residence time of 16.7 min and denotes its slow dissociation rate from ACE (Fig. 5A).
Then we performed competition SPR assay traces of SARS-CoV-2 spike
glycoprotein between ACE2 and thymosin-1. SARS-CoV-2 spike glycoprotein
was fixed on the chip and then dipped into wells containing ACE2 purified protein
alone or with doses of thymosin-1 (50 nM, 100 nM and 200 nM). It showed
that increased doses of thymosin-1 could impair the binding between
SARS-CoV-2 spike glycoprotein and ACE2 (Fig. 5B). Subsequently, purified ACE
protein and ACE2 protein were treated with doses of thymosin-1 (10
M, 20 M and 40 M). Their enzymatic activities were analyzed
as the Relative Fluorescence Unit (RFU) of the fluorometric substrates
(o-aminobenzoyl peptide for ACE and Mca-AlaPro-Lys (Dnp)-OH for ACE2). It showed
that increased doses of thymosin-1 directly suppressed the enzymatic
activity of ACE but not ACE2 (Fig. 5C).
Fig. 5.
Thymosin-1 downregulates ACE2 expressions of human
lung epithelial cells by binding with ACE. (A) Surface plasmon resonance (SPR)
analysis between thymosin-1 and ACE. The 2-fold serial dilution of
thymosin-1 was made starting from 50 nM in duplicate. Bull serum
albumin (BSA) was used as the negative control. (B) Competition SPR assay traces.
SARS-CoV-2 spike glycoprotein was fixed on the chip and then dipped into wells
containing ACE2 purified protein alone or with doses of thymosin-1. The
2-fold serial dilution of thymosin-1 was also made starting from 50 nM
in duplicate. Bull serum albumin (BSA) was used as the negative control. (C)
Kinetic activity curves of ACE and ACE2 using different doses of
thymosin-1 (10 M, 20 M and 40 M) for 30 min.
Enzymatic activities of purified ACE protein and ACE2 protein were determined by
fluorometric substrates assay, respectively. Fluorescence (Ex/Em = 320/420 nm) of
each point was measured by the standard curve. (D) Treated with increased doses
of thymosin-1 (10 M, 20 M and 40 M) for 48 hours,
the expressions of ACE and ACE2 of BEAS-2B cells and BEP-2D cells were determined
by western blotting assay, respectively. The ratios of their corresponding
grayscale values to -actin were statistically illuminated in the bottom
panels. (E) Treated with increased doses of thymosin-1 (10 M, 20
M and 40 M) for 48 hours, mRNA levels of ACE and ACE2 in BEAS-2B
cells and BEP-2D cells were determined by RT-qPCR, respectively.
CT = (CT – CT) – (CT –
CT). Data are presented as mean
SEM. *p 0.05, **p 0.01 and ***p
0.001 (Student’s t-test).
Inhibition on ACE2 expressions of human lung epithelial cells by
thymosin-1. In order to characterize the anti-COVID-19 actions of
thymosin-1 based on the above network pharmacological findings, we
performed western blotting assay to assess the effects of increased doses of
thymosin-1 (10 M, 20 M and 40 M) on ACE and ACE2
expressions of human lung epithelial cells (BEAS-2B cells and BEP-2D cells),
respectively. Interestingly, thymosin-1 rendered both BEAS-2B cells and
BEP-2D cells with significantly downregulated ACE2 expressions in a
dose-dependent way (p 0.001), but not for their ACE expressions
(Fig. 5D). Then mRNA levels of ACE and ACE2 were detected by RT-qPCR in BEAS-2B
cells and BEP-2D cells, which also demonstrated the decreased ACE2 and floating
ACE transcription levels after the treatment of thymosin-1 (10
M, 20 M and 40 M) (Fig. 5E).
Thymosin-1 significantly affected the synthesis of angiotensin (1–7)
in human lung epithelial cells. The synthesis of inactive angiotensin (1–9) from
angiotensin I (Ang I) and the catabolism of angiotensin II (Ang II) to produce
angiotensin (1–7) represent the main functions of ACE2. To further confirm the
effect of decreased ACE2 expression by thymosin-1, we thus analyzed the
synthesis of angiotensin (1–7) and angiotensin (1–9) induced by doses of
thymosin-1 (10 M, 20 M and 40 M) in
BEAS-2B cells and BEP-2D cells. The efficiency of ACE
knockdown was detected by western blotting and RT-qPCR, respectively (Fig. 6A).
Then ELISA assay revealed that increased thymosin-1 could upregulate
the expressions of Ang I and angiotensin (1–7), but downregulate the expression
of Ang II in both BEAS-2B cells and BEP-2D cells (p 0.05). In
contrast, the synthesis of angiotensin (1–9) remained unaffected (Fig. 6B). The
expressions of Ang I and angiotensin (1–7) were significantly increased by
higher dose of thymosin-1, while Ang II decreased with higher dose of
thymosin-1 and Angiotensin (1–9) was not obviously changed. But for
BEAS-2B cells and BEP-2D cells, increased levels of Ang I and
angiotensin (1–7) were significantly impaired, indicating that
thymosin-1-modulated angiotensinogen-renin system was mainly attributed
to ACE (Fig. 6B). Ang (1–7) is mostly synthesized from Ang I by three known
enzymes, including neprilysin (NEP), thimet oligopeptidase (TOP) and prolyl
oligopeptidase (POP). ACE2 also mediates the conversion of Ang II into the
enzymatic product Ang (1–7). Herein, as shown in Fig. 5C, the enzymatic
activity of ACE was significantly inhibited by thymosin-1, even more
remarkable than ACE2. Increased Ang I thus accumulated to be converted into Ang
(1–7), leading to increased expression of Ang (1–7) (Fig. 7).
Fig. 6.
Thymosin-1 significantly affected the synthesis of
angiotensin (1–7) in human lung epithelial cells. (A) The efficiency of ACE
knockdown was detected by western blotting (left panel) and RT-qPCR (right
panel). (B) ELISA assay was used to determine Ang I, Ang II, Ang (1–7) and Ang
(1–9) of BEAS-2B cells and BEP-2D cells as well as their
control cells under the exposure of thymosin-1 (10 M, 20
M and 40 M) for 48 hours, respectively. Experiments were performed
in triplicate and are expressed as mean SEM. *p 0.05,
**p 0.01 and ***p 0.001 (Student’s t-test).
Fig. 7.
Schematic representation of Thymosin-1 modulating
renin-angiotensin system. Thymosin-1 impaired the levels of
angiotensin-converting enzyme (ACE2) and angiotensin (1–7) of human lung
epithelial cells. In contrast, thymosin-1 had no impact on their ACE
and angiotensin (1–9) expressions, but directly inhibited the enzymatic activity
of ACE. Angiotensinogen (AGT) Neprilysin (NEP), Thimet oligopeptidase (TOP) and
Prolyl oligopeptidase (POP).
4. Discussion
It is well known that thymosin-1 enhances the immune response by
restoration of lymphocytopenia and reversion of exhausted T cells, but we do not
know whether thymosin-1 could affect the targets of SARS-CoV-2
infection. In this study, we provided novel insights into the mechanism of
thymosin-1 in preventing COVID-19. The major discoveries mainly
include: (1) HLA-A, FURIN, DPP4, CTSL, CTSB, ACE, PTGS2 and HLA-DRB1 are
identified as the core targets in thymosin-1 treating COVID-19; (2)
Thymosin-1 could strongly bind with ACE in the low nanomolar range; (3)
Treatment of thymosin-1 effectively downregulates ACE2 expression,
which impairs the synthesis of angiotensin (1–7) in human lung epithelial cells.
In essence, this study indicates thymosin-1 treatment could decrease
ACE2 expression in human lung epithelial cells, which implicates that
thymosin-1 might be the potential therapeutic regimen to prevent
COVID-19.
Angiotensin-converting enzyme-2 (ACE2) has been reckoned as the functional host
receptor for COVID-19 [34, 35], which is widely expressed in a variety of human
organs [36, 37]. Physiologically, ACE2 is a pivotal counter-regulatory enzyme to
ACE by breaking down angiotensin II, functioning as the core of the
renin-angiotensin-aldosterone system [38, 39]. It is concerned that ACE inhibitors
could theoretically upregulate ACE2 expression in the lungs, increasing the risk
of acquiring SARS-CoV-2 infection. However, no data till now has demonstrated
that ACE inhibitors could definitively increase lung ACE2 expression in animals
or humans. Similarly, downstream effects of these agents hardly increase viral
infectivity or virulence. Captopril, the known ACE inhibitor, was reported to
downregulate ACE2 expression in osteoporotic rats. Thus, captopril was clinically
identified to activate ACE2-dependent Mas receptor signaling in restoring bone
metabolism [40]. For cases of type II diabetic patients, renal ACE2 were
transcriptionally decreased after Losartan treatment [41]. Administration of
pioglitazone along with ACEi Enalapril were performed in the SARS-CoV-2
case-control study, which also indicates to block the overexpression of ACE2
[42]. In this study, we showed that thymosin-1 could downregulate ACE2
expression but negligibly affect ACE expression in human lung epithelial cells
(BEAS-2B cells and BEP-2D cells), which further indicated that ACE and ACE2
expressions seem not to be inherently connected.
SARS-CoV-2 infection cycle includes 5 steps: virus entry by endosomes or plasma
membrane fusion, translation of viral replication machinery, replication,
translation of viral structure proteins and virion assembly. For the entry of
SARS-CoV2, transmembrane protease serine 2 (TMPRSS2) and Paired basic Amino acid
Cleaving Enzyme (PACE or FURIN) are also important to the proteolytic activation
of SARS-CoV-2 [43], which has been enriched in 8 potential targets of
thymosin-1 (Fig. 1). Obviously, this study manifests that
thymosin-1 is mainly implicated into the first step, virus entry by
ACE2-mediated plasma membrane fusion. However, both ACE and ACE2 exist as the
membrane-bound and soluble form, with the former one predominately distributed
[44]. In this study, targets prediction and in vitro verification of
this study is limited to focus on the expression of membrane-bound ACE2 in human
respiratory epithelia. In vivo study could further help to clarify
whether thymosin-1 affected soluble ACE and ACE2 expressions in the
blood. Moreover, this study is lack of competing relationship between
thymosin-1 and SARS-CoV-2 spike in the infected models, with the
condition of laboratory biosecurity. In addition, thymosin-1 was owned
with pleiotropic functions interact with SARS-CoV-2, which cannot be simplified by
ACE inhibition. According to the bioinformatic analysis of 8 core targets,
contributions of other modulating factors also deserve further experimental
verification such as HLA-DR, the important immune activation factor that was
found to be significantly decreased in thymosin-1-treated COVID-19
patients at peripheral blood [45].
At present, no evidence has proved that patients who are taking ACE inhibitors
to treat hypertension, cardiovascular disease, chronic kidney disease are at
higher risk of SARS-CoV-2 infection or more severe COVID-19. However, several
ongoing clinical trials are implemented, which aimed to inform these decisions by
investigating the impact of withdrawal versus continuation of ACE inhibitor
medications in patients with COVID-19 (https://www.clinicaltrials.gov; Unique
identifier: NCT04338009). In fact, to avoid the serious consequences of stopping
ACE inhibitors, many societies of hypertension, cardiovascular and kidney have
stated to continually use these important medications of ACE inhibitors until the
solid evidence emerges [46].
5. Conclusions
In this study, we suggested that thymosin-1 impairs ACE2 expressions
of human lung epithelial cells by binding with ACE, thus indicating that
therapeutic strategy of thymosin-1 may help to early prevent COVID-19.
Ongoing and planned research studies should provide COVID-19 patients with safe
ACE2 upstream regulators and further explore the regulatory mechanisms behind ACE
and ACE2. Future research into renin-angiotensin-aldosterone system in patients
diagnosed with COVID-19, is urgently needed as there remain significant knowledge
gaps.
Author contributions
YMC and BZ conceived the project. YHZ, WYW, CZW and HZ performed the experiments
of molecular mechanisms. XCP and ZW performed all statistical analysis. YHZ wrote
the manuscript, which was edited by all authors.
Ethics approval and consent to participate
Not applicable.
Acknowledgment
We appreciated Xian-Jun Qu for advising and polishing the manuscript.
Funding
This research was funded by the National Key R&D Program of China, grant number
(No. 2020YFC2008304); National Natural Science Foundation of PR China, grant
number (No. 81973320 and No. 81903714); Beijing Municipal Natural Science
Foundation, grant number (No. 7171012 and No. 7204317).
Conflict of interest
The authors declare no conflict of interest.